Neurodegenerative Diseases: Expanding the Prion Concept

Annual Review of Neuroscience

Volumn 38, Issue , 2015, Pages 87-103

  Walker, Lary C ^a,b   Jucker, Mathias ^c,d  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

Author keywords

Alzheimer's disease; Amyloid; Cell to cell spreading; Disease progression; Parkinson's disease; Prion; Proteopathy; Synuclein; Tau; Transmission

Indexed keywords

AMYLOID BETA PROTEIN; PRION PROTEIN; PROTEIN AGGREGATE; TAU PROTEIN; PRION;

ALZHEIMER DISEASE; ARTICLE; BRAIN SPONGIOSIS; DEGENERATIVE DISEASE; HOST; HUMAN; NERVOUS SYSTEM; NONHUMAN; PATHOGENESIS; PRION; PRION DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; ANIMAL; METABOLISM;

ANIMALS; HUMANS; NEURODEGENERATIVE DISEASES; PRIONS;

EID: 84937392013     PISSN: 0147006X     EISSN: 15454126     Source Type: Book Series    
DOI: 10.1146/annurev-neuro-071714-033828     Document Type: Article

References (170)

1. Aguzzi A. 2003. Prions and the immune system: A journey through gut, spleen, and nerves. Adv. Immunol. 81:123-71
2. Aguzzi A, Heikenwalder M, Polymenidou M. 2007. Insights into prion strains and neurotoxicity. Nat. Rev. Mol. Cell Biol. 8:552-61
3. AhmedZ, Cooper J, MurrayTK, Garn K, McNaughtonE, et al. 2014. A novel in vivo model of tau propagation with rapid and progressive neurofibrillary tangle pathology: The pattern of spread is determined by connectivity, not proximity. Acta Neuropathol. 127:667-83
4. Al-Chalabi A, Jones A, TroakesC, King A, Al-Sarraj S, van den Berg LH. 2012. The genetics and neuropathology of amyotrophic lateral sclerosis. Acta Neuropathol. 124:339-52
5. Ano Bom APD, Rangel LP, Costa DCF, de Oliveira GAP, Sanches D, et al. 2012. Mutant p53 aggregates into prion-like amyloid oligomers and fibrils: implications for cancer. J. Biol. Chem. 287:28152-62
6. Arnold SE, Hyman BT, Flory J, Damasio AR, Van Hoesen GW. 1991. The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. Cereb. Cortex 1:103-16
7. Aulíc S, Le TTN, Moda F, Abounit S, Corvaglia S, et al. 2014. Defined synuclein prion-like molecular assemblies spreading in cell culture. BMC Neurosci. 15:69
8. Avila J, Lucas JJ, Perez M, Hernandez F. 2004. Role of tau protein in both physiological and pathological conditions. Physiol. Rev. 84:361-84
9. Baker HF, Ridley RM, Duchen LW, Crow TJ, Bruton CJ. 1993. Evidence for the experimental transmission of cerebral amyloidosis to primates. Int. J. Exp. Pathol. 74:441-54
10. Balch WE, Morimoto RI, Dillin A, Kelly JW. 2008. Adapting proteostasis for disease intervention. Science 319:916-19
11. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, et al. 2012. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N. Engl. J. Med. 367:795-804
12. Bennion Callister J, Pickering-Brown SM. 2014. Pathogenesis/genetics of frontotemporal dementia and how it relates to ALS. Exp. Neurol. 262(Part B):84-90
13. Bero AW, Yan P, Roh JH, Cirrito JR, Stewart FR, et al. 2011. Neuronal activity regulates the regional vulnerability to amyloid-deposition. Nat. Neurosci. 14:750-56
14. Boluda S, Iba M, Zhang B, Raible KM, Lee VMY, Trojanowski JQ. 2015. Differential induction and spread of tau pathology in young PS19 tau transgenic mice following intracerebral injections of pathological tau from Alzheimer's disease or corticobasal degeneration brains. Acta Neuropathol. 129:221-37
15. Braak H, Braak E. 1995. Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol. Aging 16:271-78
16. Braak H, Brettschneider J, Ludolph AC, Lee VM, Trojanowski JQ, Del Tredici K. 2013. Amyotrophic lateral sclerosis-a model of corticofugal axonal spread. Nat. Rev. Neurol. 9:708-14
17. Brettschneider J, Del Tredici K, Irwin DJ, Grossman M, Robinson JL, et al. 2014. Sequential distribution of pTDP-43 pathology in behavioral variant frontotemporal dementia (bvFTD). Acta Neuropathol. 127:423-39
18. Brown P, Brandel JP, Sato T, Nakamura Y, MacKenzie J, et al. 2012. Iatrogenic Creutzfeldt-Jakob disease, final assessment. Emerg. Infect. Dis. 18:901-7
19. Buyukmihci N, Goehring-Harmon F, Marsh RF. 1983. Neural pathogenesis of experimental scrapie after intraocular inoculation of hamsters. Exp. Neurol. 81:396-406
20. Cai X, Chen J, Xu H, Liu S, Jiang QX, et al. 2014. Prion-like polymerization underlies signal transduction in antiviral immune defense and inflammasome activation. Cell 156:1207-22
21. Caughey B, Baron GS, Chesebro B, Jeffrey M. 2009. Getting a grip on prions: oligomers, amyloids, and pathological membrane interactions. Annu. Rev. Biochem. 78:177-204
22. Chesebro B, Race R, Wehrly K, Nishio J, Bloom M, et al. 1985. Identification of scrapie prion protein-specific mRNA in scrapie-infected and uninfected brain. Nature 315:331-33
23. Chiti F, Dobson CM. 2006. Protein misfolding, functional amyloid, and human disease. Annu. Rev. Biochem. 75:333-66
24. Clavaguera F, Akatsu H, Fraser G, Crowther RA, Frank S, et al. 2013. Brain homogenates from human tauopathies induce tau inclusions in mouse brain. PNAS 110:9535-40
25. Clavaguera F, Bolmont T, Crowther RA, Abramowski D, Frank S, et al. 2009. Transmission and spreading of tauopathy in transgenic mouse brain. Nat. Cell Biol. 11:909-13
26. Clavaguera F, Hench J, Lavenir I, Schweighauser G, Frank S, et al. 2014. Peripheral administration of tau aggregates triggers intracerebral tauopathy in transgenic mice. Acta Neuropathol. 127:299-301
27. Colby DW, Wain R, Baskakov IV, Legname G, Palmer CG, et al. 2010. Protease-sensitive synthetic prions. PLOS Pathog. 6:e1000736
28. Collinge J, Clarke AR. 2007. A general model of prion strains and their pathogenicity. Science 318:930-36
29. Collins SJ, Lawson VA, Masters CL. 2004. Transmissible spongiform encephalopathies. Lancet 363:51-61
30. Cruts M, Gijselinck I, Van Langenhove T, van der Zee J, Van Broeckhoven C. 2013. Current insights into the C9orf72 repeat expansion diseases of the FTLD/ALS spectrum. Trends Neurosci. 36:450-59
31. Cushman M, Johnson BS, King OD, Gitler AD, Shorter J. 2010. Prion-like disorders: blurring the divide between transmissibility and infectivity. J. Cell Sci. 123:1191-201
32. DeArmond SJ, Prusiner SB. 1995. Etiology and pathogenesis of prion diseases. Am. J. Pathol. 146:785-811
33. de Calignon A, Polydoro M, Suarez-Calvet M, William C, Adamowicz DH, et al. 2012. Propagation of tau pathology in a model of early Alzheimer's disease. Neuron 73:685-97
34. Deleault NR, Walsh DJ, Piro JR, Wang F, Wang X, et al. 2012. Cofactor molecules maintain infectious conformation and restrict strain properties in purified prions. PNAS 109:E1938-46
35. Domert J, Rao SB, Agholme L, Brorsson AC, Marcusson J, et al. 2014. Spreading of amyloid-peptides via neuritic cell-to-cell transfer is dependent on insufficient cellular clearance. Neurobiol. Dis. 65:82-92
36. Duran-Aniotz C, Morales R, Moreno-Gonzalez I, Hu PP, Fedynyshyn J, Soto C. 2014. Aggregate-depleted brain fails to induce Adeposition in a mouse model of Alzheimer's disease. PLOS ONE 9:e89014
37. Duran-Aniotz C, Morales R, Moreno-Gonzalez I, Hu PP, Soto C. 2013. Brains from non-Alzheimer's individuals containing amyloid deposits accelerate Adeposition in vivo. Acta Neuropathol. Commun. 1:76
38. Eisele YS, Bolmont T, Heikenwalder M, Langer F, Jacobson LH, et al. 2009. Induction of cerebral amyloidosis: intracerebral versus systemic Ainoculation. PNAS 106:12926-31
39. Eisele YS, Fritschi SK, Hamaguchi T, Obermüller U, Füger P, et al. 2014. Multiple factors contribute to the peripheral induction of cerebral amyloidosis. J. Neurosci. 34:10264-73
40. Eisele YS, Obermüller U, Heilbronner G, Baumann F, Kaeser SA, et al. 2010. Peripherally applied Acontaining inoculates induce cerebral amyloidosis. Science 330:980-82
41. Eisenberg D, Jucker M. 2012. The amyloid state of proteins in human diseases. Cell 148:1188-203
42. Fast C, Groschup MH. 2013. Classical and atypical scrapie in sheep and goats. In Prions and Diseases, Vol. 2: Animals, Humans and the Environment, ed. WQ Zou, P Gambetti, pp. 15-44. New York: Springer
43. Forget KJ, Tremblay G, Roucou X. 2013. p53 Aggregates penetrate cells and induce the co-aggregation of intracellular p53. PLOS ONE 8:e69242
44. Frank SA. 2014. Somatic mosaicism and disease. Curr. Biol. 24:R577-81
45. Franklin BS, Bossaller L, De Nardo D, Ratter JM, Stutz A, et al. 2014. The adaptor ASC has extracellular and 'prionoid' activities that propagate inflammation. Nat. Immunol. 15:727-37
46. Fraser H. 1982. Neuronal spread of scrapie agent and targeting of lesions within the retino-tectal pathway. Nature 295:149-50
47. Fritschi SK, Cintron A, Ye L, Mahler J, Bühler A, et al. 2014a. Aseeds resist inactivation by formaldehyde. Acta Neuropathol. 128:477-84
48. Fritschi SK, Langer F, Kaeser SA, Maia LF, Portelius E, et al. 2014b. Highly potent soluble amyloid-seeds in human Alzheimer brain but not cerebrospinal fluid. Brain 137:2909-15
49. Frost B, Jacks RL, Diamond MI. 2009. Propagation of tau misfolding from the outside to the inside of a cell. J. Biol. Chem. 284:12845-52
50. Furukawa Y, Kaneko K, Watanabe S, Yamanaka K, Nukina N. 2011. A seeding reaction recapitulates intracellular formation of Sarkosyl-insoluble transactivation response element (TAR) DNA-binding protein-43 inclusions. J. Biol. Chem. 286:18664-72
51. Gajdusek DC. 1977. Unconventional viruses and the origin and disappearance of kuru. Science 197:943-60
52. Gambetti P, Cali I, Notari S, Kong Q, Zou WQ, Surewicz WK. 2011. Molecular biology and pathology of prion strains in sporadic human prion diseases. Acta Neuropathol. 121:79-90
53. Goedert M, Spillantini MG, Del Tredici K, Braak H. 2013. 100 years of Lewy pathology. Nat. Rev. Neurol. 9:13-24
54. Goudsmit J, Morrow CH, Asher DM, Yanagihara RT, Masters CL, et al. 1980. Evidence for and against the transmissibility of Alzheimer disease. Neurology 30:945-50
55. Grad LI, Cashman NR. 2014. Prion-like activity ofCu/Zn superoxide dismutase: implications for amyotrophic lateral sclerosis. Prion 8:33-41
56. Grad LI, Yerbury JJ, Turner BJ, Guest WC, Pokrishevsky E, et al. 2014. Intercellular propagated misfolding of wild-type Cu/Zn superoxide dismutase occurs via exosome-dependent and-independent mechanisms. PNAS 111:3620-25
57. Guo JL, Covell DJ, Daniels JP, IbaM, Stieber A, et al. 2013. Distinctsynuclein strains differentially promote tau inclusions in neurons. Cell 154:103-17
58. Guo JL, Lee VMY. 2014. Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases. Nat. Med. 20:130-38
59. Hamaguchi T, Eisele YS, Varvel NH, Lamb BT, Walker LC, JuckerM. 2012. The presence of Aseeds, and not age per se, is critical to the initiation of Adeposition in the brain. Acta Neuropathol. 123:31-37
60. Han TW, Kato M, Xie S, Wu LC, MirzaeiH, et al. 2012. Cell-free formation of RNA granules: Bound RNAs identify features and components of cellular assemblies. Cell 149:768-79
61. Hardy J, Revesz T. 2012. The spread of neurodegenerative disease. N. Engl. J. Med. 366:2126-28
62. Hardy J, Selkoe DJ. 2002. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297:353-56
63. Heilbronner G, Eisele YS, Langer F, Kaeser SA, Novotny R, et al. 2013. Seeded strain-like transmission of amyloid morphotypes in APP transgenic mice. EMBO Rep. 14:1017-22
64. Heuer E, Rosen RF, Cintron A, Walker LC. 2012. Nonhuman primate models of Alzheimer-like cerebral proteopathy. Curr. Pharm. Des. 18:1159-69
65. Holtzman DM, Morris JC, Goate AM. 2011. Alzheimer's disease: the challenge of the second century. Sci. Transl. Med. 3:77sr1
66. Horvath S. 2013. DNA methylation age of human tissues and cell types. Genome Biol. 14:R115
67. Hou F, Sun L, Zheng H, Skaug B, Jiang QX, Chen ZJ. 2011. MAVS forms functional prion-like aggregates to activate and propagate antiviral innate immune response. Cell 146:448-61
68. Iba M, Guo JL, McBride JD, Zhang B, Trojanowski JQ, Lee VMY. 2013. Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of Alzheimer's-like tauopathy. J. Neurosci. 33:1024-37
69. Irwin DJ, Abrams JY, Schonberger LB, Leschek EW, Mills JL, et al. 2013. Evaluation of potential infectivity of Alzheimer and Parkinson disease proteins in recipients of cadaver-derived human growth hormone. JAMA Neurol. 70:462-68
70. Iturria-Medina Y, Sotero RC, Toussaint PJ, EvansAC, Alzheimer'sDis. Neuroimaging Initiat. 2014. Epidemic spreading model to characterize misfolded proteins propagation in aging and associated neurodegenerative disorders. PLOS Comput. Biol. 10:e1003956
71. Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, et al. 2010. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 9:119-28
72. Johnson RT. 2005. Prion diseases. Lancet Neurol. 4:635-42
73. Jucker M. 2010. The benefits and limitations of animal models for translational research in neurodegenerative diseases. Nat. Med. 16:1210-14
74. Jucker M, Walker LC. 2011. Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders. Ann. Neurol. 70:532-40
75. Jucker M, Walker LC. 2013. Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature 501:45-51
76. Kane MD, Lipinski WJ, Callahan MJ, Bian F, Durham RA, et al. 2000. Evidence for seeding of amyloid by intracerebral infusion of Alzheimer brain extracts in amyloid precursor protein-transgenic mice. J. Neurosci. 20:3606-11
77. Kato M, Han TW, Xie S, Shi K, Du X, et al. 2012. Cell-free formation of RNA granules: Low complexity sequence domains form dynamic fibers within hydrogels. Cell 149:753-67
78. Kim HJ, Kim NC, Wang YD, Scarborough EA, Moore J, et al. 2013. Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. Nature 495:467-73
79. Kimberlin RH, Walker CA. 1986. Pathogenesis of scrapie (strain 263K) in hamsters infected intracerebrally, intraperitoneally or intraocularly. J. Gen. Virol. 67(Part 2):255-63
80. King OD, Gitler AD, Shorter J. 2012. The tip of the iceberg: RNA-binding proteins with prion-like domains in neurodegenerative disease. Brain Res. 1462:61-80
81. Knowles TP, VendruscoloM, DobsonCM. 2014. The amyloid state and its associationwith protein misfolding diseases. Nat. Rev. Mol. Cell Biol. 15:384-96
82. Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW. 2008. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat. Med. 14:504-6
83. Krauss S, Vorberg I. 2013. Prions ex vivo: what cell culture models tell us about infectious proteins. Int. J. Cell Biol. 2013:704546
84. Langer F, Eisele YS, Fritschi SK, Staufenbiel M, Walker LC, Jucker M. 2011. Soluble Aseeds are potent inducers of cerebral amyloid deposition. J. Neurosci. 31:14488-95
85. Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Guerrero-Munoz MJ, Kiritoshi T, et al. 2012. Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau. Sci. Rep. 2:700
86. Lee VMY, Goedert M, Trojanowski JQ. 2001. Neurodegenerative tauopathies. Annu. Rev. Neurosci. 24:1121-59
87. Li JY, Englund E, Holton JL, Soulet D, Hagell P, et al. 2008. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat. Med. 14:501-3
88. Li YR, King OD, Shorter J, Gitler AD. 2013. Stress granules as crucibles of ALS pathogenesis. J. Cell Biol. 201:361-72
89. Liberski PP, Hainfellner JA, Sikorska B, Budka H. 2012. Prion protein (PrP) deposits in the tectum of experimental Gerstmann-Straüssler-Scheinker disease following intraocular inoculation. Folia Neuropathol. 50:85-88
90. Liebman SW, Chernoff YO. 2012. Prions in yeast. Genetics 191:1041-72
91. Ling SC, Polymenidou M, Cleveland DW. 2013. Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron 79:416-38
92. Liu L, Drouet V, Wu JW, Witter MP, Small SA, et al. 2012. Trans-synaptic spread of tau pathology in vivo. PLOS ONE 7:e31302
93. Lladó L, Baliellas C, Casasnovas C, Ferrer I, Fabregat J, et al. 2010. Risk of transmission of systemic transthyretin amyloidosis after domino liver transplantation. Liver Transplant. 16:1386-92
94. Lu JX, QiangW, Yau WM, Schwieters CD, Meredith SC, Tycko R. 2013. Molecular structure of amyloid fibrils in Alzheimer's disease brain tissue. Cell 154:1257-68
95. Luk KC, Kehm V, Carroll J, Zhang B, O'Brien P, et al. 2012a. Pathological synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338:949-53
96. Luk KC, Kehm VM, Zhang B, O'Brien P, Trojanowski JQ, Lee VMY. 2012b. Intracerebral inoculation of pathological synuclein initiates a rapidly progressive neurodegenerative synucleinopathy in mice. J. Exp. Med. 209:975-86
97. Luk KC, Song C, O'Brien P, Stieber A, Branch JR, et al. 2009. Exogenous synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. PNAS 106:20051-56
98. Maji SK, Perrin MH, Sawaya MR, Jessberger S, Vadodaria K, et al. 2009. Functional amyloids as natural storage of peptide hormones in pituitary secretory granules. Science 325:328-32
99. Masuda-Suzukake M, Nonaka T, Hosokawa M, Kubo M, Shimozawa A, et al. 2014. Pathological alphasynuclein propagates through neural networks. Acta Neuropathol. Commun. 2:88
100. Masuda-SuzukakeM, Nonaka T, HosokawaM, Oikawa T, Arai T, et al. 2013. Prion-like spreading of pathological synuclein in brain. Brain 136:1128-38
101. McConnell MJ, Lindberg MR, Brennand KJ, Piper JC, Voet T, et al. 2013. Mosaic copy number variation in human neurons. Science 342:632-37
102. Mehta AK, Rosen RF, Childers WS, Gehman JD, Walker LC, Lynn DG. 2013. Context dependence of protein misfolding and structural strains in neurodegenerative diseases. Biopolymers 100:722-30
103. Meinhardt J, Sachse C, Hortschansky P, Grigorieff N, Fändrich M. 2009. A(1-40) fibril polymorphism implies diverse interaction patterns in amyloid fibrils. J. Mol. Biol. 386:869-77
104. Meyer-Luehmann M, Coomaraswamy J, Bolmont T, Kaeser S, Schaefer C, et al. 2006. Exogenous induction of cerebral amyloidogenesis is governed by agent and host. Science 313:1781-84
105. Mizielinska S, Grönke S, Niccoli T, Ridler CE, Clayton EL, et al. 2014. C9orf72 repeat expansions cause neurodegeneration in Drosophila through arginine-rich proteins. Science 345:1192-94
106. Morales R, Duran-AniotzC, Castilla J, Estrada LD, Soto C. 2012. De novo induction of amyloid-deposition in vivo. Mol. Psychiatry 17:1347-53
107. Mougenot AL, Nicot S, Bencsik A, Morignat E, Verchere J, et al. 2012. Prion-like acceleration of a synucleinopathy in a transgenic mouse model. Neurobiol. Aging 33:2225-28
108. Munch C, O'Brien J, Bertolotti A. 2011. Prion-like propagation of mutant superoxide dismutase-1 misfolding in neuronal cells. PNAS 108:3548-53
109. Murakami T, Ishiguro N, Higuchi K. 2014. Transmission of systemic AA amyloidosis in animals. Vet. Pathol. 51:363-71
110. Nath S, Agholme L, Kurudenkandy FR, Granseth B, Marcusson J, HallbeckM. 2012. Spreading of neurodegenerative pathology via neuron-to-neuron transmission of amyloid. J. Neurosci. 32:8767-77
111. Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, et al. 2012. Correlation of Alzheimer disease neuropathologic changes with cognitive status: A review of the literature. J. Neuropathol. Exp. Neurol. 71:362-81
112. Newby GA, Lindquist S. 2013. Blessings in disguise: biological benefits of prion-like mechanisms. Trends Cell Biol. 23:251-59
113. Nilsson KPR, A slund A, Berg I, Nyström S, Konradsson P, et al. 2007. Imaging distinct conformational states of amyloid-fibrils in Alzheimer's disease using novel luminescent probes. ACS Chem. Biol. 2:553-60
114. Nonaka T, Masuda-Suzukake M, Arai T, Hasegawa Y, Akatsu H, et al. 2013. Prion-like properties of pathological TDP-43 aggregates from diseased brains. Cell Rep. 4:124-34
115. Oesch B, Westaway D, Wälchli M, McKinley MP, Kent SBH, et al. 1985. A cellular gene encodes scrapie PrP 27-30 protein. Cell 40:735-46
116. Paravastu AK, Leapman RD, Yau WM, Tycko R. 2008. Molecular structural basis for polymorphism in Alzheimer's amyloid fibrils. PNAS 105:18349-54
117. Paravastu AK, Qahwash I, Leapman RD, Meredith SC, Tycko R. 2009. Seeded growth of amyloid fibrils from Alzheimer's brain-derived fibrils produces a distinct fibril structure. PNAS 106:7443-48
118. Parchi P, GieseA, Capellari S, Brown P, Schulz-SchaefferW, et al. 1999. Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects. Ann. Neurol. 46:224-33
119. Pecho-Vrieseling E, RiekerC, Fuchs S, BleckmannD, EspositoMS, et al. 2014. Transneuronal propagation of mutant huntingtin contributes to non-cell autonomous pathology in neurons. Nat. Neurosci. 17:1064-72
120. Peeraer E, Bottelbergs A, Van Kolen K, Stancu IC, Vasconcelos B, et al. 2015. Intracerebral injection of preformed synthetic tau fibrils initiates widespread tauopathy and neuronal loss in the brains of tau transgenic mice. Neurobiol. Dis. 73:83-95
121. Petkova AT, Leapman RD, Guo Z, Yau WM, Mattson MP, Tycko R. 2005. Self-propagating, molecular-level polymorphism in Alzheimer's amyloid fibrils. Science 307:262-65
122. Prusiner SB. 1982. Novel proteinaceous infectious particles cause scrapie. Science 216:136-44
123. Prusiner SB. 1984. Some speculations about prions, amyloid, and Alzheimer's disease. N. Engl. J. Med. 310:661-63
124. Prusiner SB. 1998. Prions. PNAS 95:13363-83
125. Prusiner SB. 2012. A unifying role for prions in neurodegenerative diseases. Science 336:1511-13
126. Prusiner SB. 2013. Biology and genetics of prions causing neurodegeneration. Annu. Rev. Genet. 47:601-23
127. Rademakers R, Neumann M, Mackenzie IR. 2012. Advances in understanding the molecular basis of frontotemporal dementia. Nat. Rev. Neurol. 8:423-34
128. Raj A, LoCastro E, Kuceyeski A, Tosun D, Relkin N, et al. 2015. Network diffusion model of progression predicts longitudinal patterns of atrophy and metabolism in Alzheimer's disease. Cell Rep. 10:359-69
129. Rangel LP, Costa DCF, Vieira TCRG, Silva JL. 2014. The aggregation of mutant p53 produces prion-like properties in cancer. Prion 8:75-84
130. Raveendra BL, Siemer AB, Puthanveettil SV, Hendrickson WA, Kandel ER, McDermott AE. 2013. Characterization of prion-like conformational changes of the neuronal isoform of Aplysia CPEB. Nat. Struct. Mol. Biol. 20:495-501
131. Ravits JM, La Spada AR. 2009. ALS motor phenotype heterogeneity, focality, and spread: deconstructing motor neuron degeneration. Neurology 73:805-11
132. Recasens A, Dehay B, Bové J, Carballo-Carbajal I, Dovero S, et al. 2014. Lewy body extracts from Parkinson disease brains trigger synuclein pathology and neurodegeneration in mice and monkeys. Ann. Neurol. 75:351-62
133. Ren PH, Lauckner JE, Kachirskaia I, Heuser JE, Melki R, Kopito RR. 2009. Cytoplasmic penetration and persistent infection of mammalian cells by polyglutamine aggregates. Nat. Cell Biol. 11:219-25
134. Rosen RF, Ciliax BJ, Wingo TS, Gearing M, Dooyema J, et al. 2010. Deficient high-affinity binding of Pittsburgh compound B in a case of Alzheimer's disease. Acta Neuropathol. 119:221-33
135. Rosen RF, Fritz JJ, Dooyema J, Cintron AF, Hamaguchi T, et al. 2012. Exogenous seeding of cerebral amyloid deposition in APP-transgenic rats. J. Neurochem. 120:660-66
136. Rosen RF, Walker LC, LeVine H III. 2011. PIB binding in aged primate brain: enrichment of high-affinity sites in humans with Alzheimer's disease. Neurobiol. Aging 32:223-34
137. Safar J, Wille H, Itri V, GrothD, SerbanH, et al. 1998. Eight prion strains have PrPSc molecules with different conformations. Nat. Med. 4:1157-65
138. Sanders DW, Kaufman SK, DeVos SL, Sharma AM, Mirbaha H, et al. 2014. Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron 82:1271-88
139. SaperCB, Wainer BH, GermanDC. 1987. Axonal and transneuronal transport in the transmission of neurological disease: potential role in system degenerations, including Alzheimer's disease. Neuroscience 23:389-98
140. Saunders SE, Bartelt-Hunt SL, Bartz JC. 2012. Occurrence, transmission, and zoonotic potential of chronic wasting disease. Emerg. Infect. Dis. 18:369-76
141. Selkoe DJ. 2012. Preventing Alzheimer's disease. Science 337:1488-92
142. Si K, Lindquist S, Kandel ER. 2003. A neuronal isoform of the Aplysia CPEB has prion-like properties. Cell 115:879-91
143. Silveira JR, Raymond GJ, Hughson AG, Race RE, Sim VL, et al. 2005. The most infectious prion protein particles. Nature 437:257-61
144. Sipe JD, BensonMD, Buxbaum JN, Ikeda S, MerliniG, et al. 2014. Nomenclature 2014: Amyloid fibril proteins and clinical classification of the amyloidosis. Amyloid 21:221-24
145. Song HL, Shim S, Kim DH, Won SH, Joo S, et al. 2014. Amyloid is transmitted via neuronal connections along axonal membranes. Ann. Neurol. 75:88-97
146. Spillantini MG, Goedert M. 2013. Tau pathology and neurodegeneration. Lancet Neurol. 12:609-22
147. Stedman TL. 2012. Stedman's Medical Dictionary for the Health Professions and Nursing. Philadelphia: Wolters Kluwer/LippincottWilliams &Wilkins
148. Stöhr J, Condello C, Watts JC, Bloch L, Oehler A, et al. 2014. Distinct synthetic Aprion strains producing different amyloid deposits in bigenic mice. PNAS 111:10329-34
149. Stöhr J, Watts JC, Mensinger ZL, Oehler A, Grillo SK, et al. 2012. Purified and synthetic Alzheimer's amyloid beta (A) prions. PNAS 109:11025-30
150. Sugiyama S, Tanaka M. 2014. Self-propagating amyloid as a critical regulator for diverse cellular functions. J. Biochem. 155:345-51
151. Tanaka M, Collins SR, Toyama BH, Weissman JS. 2006. The physical basis of how prion conformations determine strain phenotypes. Nature 442:585-89
152. Tuite MF. 2013. The natural history of yeast prions. Adv. Appl. Microbiol. 84:85-137
153. Udan M, Baloh RH. 2011. Implications of the prion-related Q/N domains in TDP-43 and FUS. Prion 5:1-5
154. Van Langenhove T, van der Zee J, Van Broeckhoven C. 2012. The molecular basis of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum. Ann. Med. 44:817-28
155. Volpicelli-Daley LA, Luk KC, Patel TP, Tanik SA, Riddle DM, et al. 2011. Exogenous synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 72:57-71
156. Walker LC, Callahan MJ, Bian F, Durham RA, Roher AE, LipinskiWJ. 2002. Exogenous induction of cerebral amyloidosis in APP-transgenic mice. Peptides 23:1241-47
157. Walker LC, LeVineHIII. 2012. Corruption and spread of pathogenic proteins in neurodegenerative diseases. J. Biol. Chem. 287:33109-15
158. Wang F, Wang X, Yuan CG, Ma J. 2010. Generating a prion with bacterially expressed recombinant prion protein. Science 327:1132-35
159. Watts JC, Condello C, Stöhr J, Oehler A, Lee J, et al. 2014. Serial propagation of distinct strains of Aprions from Alzheimer's disease patients. PNAS 111:10323-28
160. Watts JC, Giles K, Grillo SK, Lemus A, DeArmond SJ, Prusiner SB. 2011. Bioluminescence imaging of Adeposition in bigenic mouse models of Alzheimer's disease. PNAS 108:2528-33
161. Watts JC, Giles K, Oehler A, Middleton L, Dexter DT, et al. 2013. Transmission of multiple system atrophy prions to transgenic mice. PNAS 110:19555-60
162. Westermark GT, Westermark P. 2010. Prion-like aggregates: infectious agents in human disease. Trends Mol. Med. 16:501-7
163. WicknerRB, EdskesHK, Bateman DA, Kelly AC, Gorkovskiy A, et al. 2013. Amyloids and yeast prion biology. Biochemistry 52:1514-27
164. Williams ES. 2005. Chronic wasting disease. Vet. Pathol. 42:530-49
165. Wu JW, HermanM, Liu L, Simoes S, Acker CM, et al. 2013. Small misfolded Tau species are internalized via bulk endocytosis and anterogradely and retrogradely transported in neurons. J. Biol. Chem. 288:1856-70
166. Xing Y, Nakamura A, ChibaT, KogishiK, MatsushitaT, et al. 2001. Transmission of mouse senile amyloidosis. Lab. Investig. 81:493-99
167. Xu J, Reumers J, Couceiro JR, De Smet F, Gallardo R, et al. 2011. Gain of function of mutant p53 by coaggregation with multiple tumor suppressors. Nat. Chem. Biol. 7:285-95
168. Ye L, Hamaguchi T, Fritschi SK, Eisele YS, Obermüller U, et al. 2015. Progression of seed-induced Adeposition within the limbic connectome. Brain Pathol. In press. doi: 10. 1111/bpa. 12252
169. Zhang Y, Wang F, Wang X, Zhang Z, Xu Y, et al. 2014. Comparison of 2 synthetically generated recombinant prions. Prion 8:215-20
170. Zhou J, Gennatas ED, Kramer JH, Miller BL, Seeley WW. 2012. Predicting regional neurodegeneration from the healthy brain functional connectome. Neuron 73:1216-27